Glaukos Corporation (GKOS)

Glaukos: The Second J-Code Rewrites The Risk Math

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

Glaukos says late-stage eye disease treatment shows lasting benefits after single dose

Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28

Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now

Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus

Glaukos Corporation $GKOS Shares Sold by Squarepoint Ops LLC

Corient Private Wealth LP Takes Position in Glaukos Corporation $GKOS

Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?

Glaukos Corporation $GKOS Stock Holdings Trimmed by Algert Global LLC

61,957 Shares in Glaukos Corporation $GKOS Purchased by Deutsche Bank AG

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Which Small-Cap ETF Is the Better Buy: iShares' Growth-Focused IWO or Invesco's Revenue-Weighted RWJ?